12 completed, 6 recruiting, 5 active not recruiting, 5 unknown. 23 Phase 2, 8 Phase 1, 2 Phase 3.
Follow brigatinib: new trials by email Literature Review of brigatinib trials Research Report on brigatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using Tumor Models to Determine Treatments Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 25 | 2025-04-07 | 2026-06-23 |
| Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) Brigatinib, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-12-11 | 2025-04-24 | |
| ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer Alectinib, Brigatinib, Lorlatinib 100 mg - NSCLC Stage IV, Sex Disorder | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 80 | 2024-08-05 | 2024-08-09 | |
| Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer Brigatinib, Durvalumab - NSCLC, Stage III, ALK-rearrangement | Phase 2 | Withdrawn | ETOP IBCSG Partners Foundation | 2024-06-07 | 2024-10-08 | |
| A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) Brigatinib - Non-small Cell Lung Cancer (NSCLC) | Active not recruiting | Takeda | 154 | 2024-01-17 | 2026-02-18 | |
| A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults Brigatinib - Healthy Volunteers | Phase 1 | Completed | Takeda | 12 | 2023-12-20 | 2025-01-23 |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer | Completed | Pfizer | 5279 | 2023-06-23 | 2025-03-30 | |
| Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor | Phase 1 / Phase 2 | Recruiting | Princess Maxima Center for Pediatric Oncology | 65 | 2022-08-18 | 2025-12-05 |
| A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions. Brigatinib - Non-small Cell Lung Cancer | Phase 2 | Unknown | Yonsei University | 12 | 2022-06-01 | 2022-05-04 |
| Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) Brigatinib 180 MG, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer, ALK Gene Mutation | Phase 2 | Active not recruiting | Intergroupe Francophone de Cancerologie Thoracique | 110 | 2022-05-18 | 2025-11-17 |
| ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma Crizotinib - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 90 | 2021-11-13 | 2024-09-20 |
| Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer Brigatinib - Non-small Cell Lung Cancer (NSCLC) | Recruiting | Takeda | 500 | 2021-11-01 | 2026-03-17 | |
| Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) Biopsy (tissue or liquid) - ALK Gene Mutation, NSCLC Stage IV | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 108 | 2021-07-12 | 2024-07-31 | |
| Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. crizotinib, alectinib, brigatinib - ALK-positive NSCLC | Completed | Pfizer | 549 | 2020-12-14 | 2023-04-06 | |
| Brigatinib Before Brain Irradiation Trial (B3i Trial) Brigatinib - Brain Metastases, Lung Cancer | Phase 2 | Terminated | University of Colorado, Denver | 1 | 2020-11-17 | 2022-10-24 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors Brigatinib, Brigatinib AAF - Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors | Phase 1 / Phase 2 | Withdrawn | Takeda | 2020-09-01 | 2020-03-05 | |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Recruiting | Scott R. Plotkin, MD, PhD | 109 | 2020-06-20 | 2026-11-12 |
| Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays Brigatinib - Non Small Cell Lung Cancer | Phase 2 | Unknown | JI-YOUN HAN | 35 | 2020-05-15 | 2023-09-28 |
| Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients Brigatinib - Lung Cancer, NSCLC | Phase 2 | Active not recruiting | Fundación GECP | 33 | 2020-05-04 | 2026-02-04 |
Showing 20 of 38. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (23) · Lung Neoplasms (9) · Carcinoma (4) · Lymphoma, Large-Cell, Anaplastic (4) · Adenocarcinoma (2) · Brain Neoplasms (2) · Carcinoma, Large Cell (2) · Carcinoma, Squamous Cell (2) · Breast Neoplasms (1) · Carcinoma, Pancreatic Ductal (1) · Disease Progression (1) · Ependymoma (1) · Erectile Dysfunction (1) · Eunuchism (1) · Gastrointestinal Neoplasms (1)
Takeda (8) · Ariad Pharmaceuticals (5) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Hunan Province Tumor Hospital (2) · M.D. Anderson Cancer Center (2) · Pfizer (2) · City of Hope Medical Center (1) · Criterium, Inc. (1) · ETOP IBCSG Partners Foundation (1) · Fondazione per la Medicina Personalizzata (1) · Fox Chase Cancer Center (1) · Fundación GECP (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Intergroupe Francophone de Cancerologie Thoracique (1) · JI-YOUN HAN (1)
United States (15) · Italy (8) · France (7) · Spain (6) · China (5) · South Korea (5) · Canada (4) · Germany (4) · Netherlands (4) · Sweden (4) · Austria (3) · Hong Kong (3) · Japan (3) · Taiwan (3) · Australia (2)
Yasir Y Elamin, MD (2) · Yongchang Zhang, MD (2) · Andrea Botticelli (1) · Chad Rusthoven, MD (1) · Collin Blakely, MD, PhD (1) · Jessica J Lin (1) · Mariano Provencio, MD (1) · Michel Zwaan, Prof (1)
PMID 29768119, PMID 41110382, PMID 23411383, PMID 27836716, PMID 28501139, PMID 30280657, PMID 31125274, PMID 32780660, PMID 33039599, PMID 33569983, PMID 34182952, PMID 34423676, PMID 36036294, PMID 36096442, PMID 36579743, PMID 37574132, PMID 38904277, PMID 39707229, PMID 41023484, PMID 41410381, PMID 41740899, PMID 41963505
2018 (4), 2015 (1), 2019 (1), P30CA016058 (1), P30CA046934 (1), P30CA060553 (1), U10CA180868 (1)